S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
NASDAQ:RXRX

Recursion Pharmaceuticals (RXRX) Competitors

$8.93
+0.27 (+3.12%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$8.43
$9.04
50-Day Range
$4.56
$9.25
52-Week Range
$4.54
$14.18
Volume
1.75 million shs
Average Volume
1.40 million shs
Market Capitalization
$1.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.40

RXRX vs. VCEL, BCRX, KYMR, SWTX, IOVA, ACLX, RLAY, PRME, SANA, and IBRX

Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Vericel (VCEL), BioCryst Pharmaceuticals (BCRX), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), Relay Therapeutics (RLAY), Prime Medicine (PRME), Sana Biotechnology (SANA), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.

Recursion Pharmaceuticals vs.

Recursion Pharmaceuticals (NASDAQ:RXRX) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.

63.6% of Recursion Pharmaceuticals shares are held by institutional investors. 22.3% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vericel has a net margin of -10.11% compared to Recursion Pharmaceuticals' net margin of -533.45%. Vericel's return on equity of -9.26% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals -533.45% -57.15% -38.10%
Vericel -10.11% -9.26% -6.64%

Vericel received 314 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 62.81% of users gave Vericel an outperform vote while only 41.38% of users gave Recursion Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Recursion PharmaceuticalsOutperform Votes
12
41.38%
Underperform Votes
17
58.62%
VericelOutperform Votes
326
62.81%
Underperform Votes
193
37.19%

Recursion Pharmaceuticals has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Vericel. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 3 mentions for Vericel. Vericel's average media sentiment score of 1.30 beat Recursion Pharmaceuticals' score of 1.05 indicating that Vericel is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vericel
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vericel has higher revenue and earnings than Recursion Pharmaceuticals. Vericel is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$39.84 million43.12-$239.48 million-$1.38-6.47
Vericel$163.70 million9.75-$16.71 million-$0.37-90.67

Recursion Pharmaceuticals currently has a consensus target price of $12.40, suggesting a potential upside of 38.86%. Vericel has a consensus target price of $37.25, suggesting a potential upside of 11.03%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Vericel
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Vericel beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.72B$2.52B$4.48B$6.15B
Dividend YieldN/A2.33%2.40%6.17%
P/E Ratio-6.473.4498.6811.85
Price / Sales43.12153.873,580.89108.36
Price / CashN/A16.1221.9322.80
Price / Book3.523.234.575.32
Net Income-$239.48M$52.38M$116.02M$192.99M
7 Day Performance9.98%-3.12%-2.22%0.40%
1 Month Performance87.21%7.18%5.77%2.52%
1 Year Performance44.73%10.14%20.09%-0.19%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCEL
Vericel
1.3271 of 5 stars
$35.17
+1.9%
$37.25
+5.9%
+19.5%$1.67B$163.70M-95.05281
BCRX
BioCryst Pharmaceuticals
2.0409 of 5 stars
$8.77
+2.3%
$15.00
+71.0%
-17.9%$1.66B$270.83M-7.25358Positive News
KYMR
Kymera Therapeutics
1.6927 of 5 stars
$29.30
-1.1%
$47.22
+61.2%
+95.5%$1.62B$46.83M-10.21141
SWTX
SpringWorks Therapeutics
1.7688 of 5 stars
$32.23
-1.5%
$56.33
+74.8%
+51.0%$2.02B$35M-6.26176Positive News
IOVA
Iovance Biotherapeutics
2.247 of 5 stars
$9.06
+13.4%
$17.70
+95.4%
+7.5%$2.03BN/A-3.77319Analyst Revision
Gap Up
High Trading Volume
ACLX
Arcellx
1.6512 of 5 stars
$43.41
+1.9%
$50.38
+16.1%
+268.7%$2.08BN/A-10.0078
RLAY
Relay Therapeutics
1.8827 of 5 stars
$11.70
+5.4%
$29.25
+150.0%
-36.5%$1.42B$1.38M-4.16245
PRME
Prime Medicine
0 of 5 stars
$14.20
-0.5%
N/AN/A$1.38B$5.21M0.00N/AInsider Selling
News Coverage
Negative News
SANA
Sana Biotechnology
1.7719 of 5 stars
$7.09
-5.8%
$10.00
+41.0%
+27.4%$1.36BN/A-4.20383Insider Selling
High Trading Volume
IBRX
ImmunityBio
2.0782 of 5 stars
$2.79
flat
$6.00
+115.1%
-35.2%$1.22B$240,000.000.00587Short Interest ↓

Related Companies and Tools

This page (NASDAQ:RXRX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -